Contact Information: Contact information: Thomas D. Ingolia CEO Email Contact: 480-385-3800
HEPI Pharmaceuticals, Inc. Files Patent Application to Protect Potential Active Components of ProAlgaZyme(R)
| Source: Health Enhancement Products, Inc.
SCOTTSDALE, AZ,--(Marketwire - June 27, 2007) - HEPI Pharmaceuticals, Inc., a subsidiary of
Health Enhancement Products, Inc. (OTCBB : HEPI ), the makers of
ProAlgaZyme®, announced today the filing of a Provisional Application for
Patent in the United States. The application is the result of recent
discoveries building on research over the past several years on the
chemical and biological analysis of ProAlgaZyme®. These discoveries,
including newly identified components, shed light on recent results of
clinical trials which indicate that ProAlgaZyme has the potential to reduce
key markers of inflammation by 57% on average. The patent filing is
designed to help protect the potential pharmaceutical opportunities
represented by the potential active components of ProAlgaZyme®.
About ProAlgaZyme® and HEPI Pharmaceuticals, Inc.
ProAlgaZyme® is a nutraceutical product of Health Enhancement Products,
Inc., the Company's parent, which is manufactured using only pure,
all-natural ingredients. ProAlgaZyme® is a liquid product produced from
algae grown in 100% distilled water. The liquid in which the algae are
grown is drawn off, filtered, tested and bottled as ProAlgaZyme®. HEPI
Pharmaceuticals, Inc., a wholly owned subsidiary of Health Enhancement
Products, Inc., is focused on development of potential pharmaceutical
opportunities represented by ProAlgaZyme®.
Except for any historical information, the matters discussed in this press
release contain forward-looking statements within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. These forward-looking statements involve risks and
uncertainties. A number of factors could cause actual results to differ
from those indicated in the forward-looking statements, including the
timing of completion of a trial, actual future clinical trial results being
different than the results the company has obtained to date, our inability
to obtain regulatory approvals necessary to market and sell PAZ as a
pharmaceutical, and the company's ability to secure funding, including for
the subsidiary's pharmaceutical development of PAZ. Such statements are
subject to a number of assumptions, risks and uncertainties. Readers are
cautioned that such statements are not guarantees of future performance and
that actual results or developments may differ materially from those set
forth in the forward-looking statements. The company undertakes no
obligation to publicly update or revise forward-looking statements, whether
as a result of new information or otherwise.
For more information, please visit www.heponline.com.